DK0640344T3 - Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform - Google Patents

Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform

Info

Publication number: DK0640344T3
Authority: DK; Denmark
Prior art keywords: active compound; children; addition; liquid; bitterness
Prior art date: 1993-08-30

Application number

DK94810472T

Other languages

English (en)

Inventor

Josef Olaf Widauer

Original Assignee

Medichemie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-30

Filing date

1994-08-16

Publication date

1999-07-05

1994-08-16 Application filed by Medichemie Ag filed Critical Medichemie Ag

1999-07-05 Application granted granted Critical

1999-07-05 Publication of DK0640344T3 publication Critical patent/DK0640344T3/da

Links

RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 title abstract 3
229960001661 ursodiol Drugs 0.000 title abstract 3
239000007788 liquid Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 abstract 2
235000019658 bitter taste Nutrition 0.000 abstract 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
229920000858 Cyclodextrin Polymers 0.000 abstract 1
239000001116 FEMA 4028 Substances 0.000 abstract 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
229960004853 betadex Drugs 0.000 abstract 1
239000003613 bile acid Substances 0.000 abstract 1
230000001587 cholestatic effect Effects 0.000 abstract 1
239000002270 dispersing agent Substances 0.000 abstract 1
239000000796 flavoring agent Substances 0.000 abstract 1
235000019634 flavors Nutrition 0.000 abstract 1
239000008297 liquid dosage form Substances 0.000 abstract 1
208000019423 liver disease Diseases 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1
230000008961 swelling Effects 0.000 abstract 1
235000019640 taste Nutrition 0.000 abstract 1
239000002562 thickening agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

DK94810472T 1993-08-30 1994-08-16 Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform DK0640344T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH256793		1993-08-30

Publications (1)

Publication Number	Publication Date
DK0640344T3 true DK0640344T3 (da)	1999-07-05

Family

ID=4236712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94810472T DK0640344T3 (da)	1993-08-30	1994-08-16	Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform

Country Status (8)

Country	Link
US (1)	US5534505A (da)
EP (1)	EP0640344B1 (da)
JP (1)	JP3631782B2 (da)
AT (1)	ATE171874T1 (da)
CA (1)	CA2130787C (da)
DE (1)	DE59407041D1 (da)
DK (1)	DK0640344T3 (da)
ES (1)	ES2121599T3 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050158408A1 (en) *	1998-07-24	2005-07-21	Yoo Seo H.	Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
RU2224523C2 (ru) *	1998-07-24	2004-02-27	Сео Хонг Ю	Водный раствор, содержащий желчную кислоту, и способ его получения
US7303768B2 (en) *	1998-07-24	2007-12-04	Seo Hong Yoo	Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) *	2004-10-15	2010-08-10	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
AU3668501A (en) *	2000-02-04	2001-08-14	Seo Hong Yoo	Preparation of aqueous clear solution dosage forms with bile acids
ES2264925T3 (es) *	2000-04-20	2007-02-01	Bioprogress S.P.A.	Metodo para convertir el acido ursodeoxilico en composiciones farmaceuticas solubles.
US7145125B2 (en)	2003-06-23	2006-12-05	Advanced Optical Technologies, Llc	Integrating chamber cone light using LED sources
EP1681065A4 (en) *	2003-10-31	2011-12-28	Wakamoto Pharma Co Ltd	WATER-BASED COMPOSITION SUBJECTED TO REVERSIBLE THERMOREGULATION
EP1771161B1 (en) *	2004-07-22	2010-04-21	Bend Research, Inc	Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
CA2577268A1 (en) *	2004-08-30	2006-03-09	Seo Hong Yoo	Neuroprotective effect of solubilized udca in focal ischemic model
ATE506955T1 (de) *	2004-10-15	2011-05-15	Seo Hong Yoo	Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
WO2006050165A2 (en) *	2004-11-01	2006-05-11	Seo Hong Yoo	Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
WO2008025560A1 (en) *	2006-09-01	2008-03-06	Pari Pharma Gmbh	Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
JP2010503667A (ja) *	2006-09-15	2010-02-04	ホンユー，ソ	大腸疾患用胆汁製剤
GB0817969D0 (en) *	2008-10-01	2008-11-05	Axcess Ltd	Pharmaceutical composition
EP2208497A1 (en)	2009-01-15	2010-07-21	Charité-Universitätsmedizin Berlin (Charité)	Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient
BR112014010228B1 (pt)	2011-10-28	2020-09-29	Lumena Pharmaceuticals Llc	Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
US10016357B2 (en) *	2012-03-22	2018-07-10	The Beauty Factory, Llc	Personal lubricants
EP3012209B1 (en)	2013-06-21	2019-05-08	Dode S.A.	Collapsible container
WO2016019066A1 (en) *	2014-07-29	2016-02-04	University Of Tennessee Research Foundation	Composition and method for treating liver disease
EP4061333B1 (en) *	2019-11-22	2025-01-22	Shilpa Medicare Limited	Injectable compositions of ursodeoxycholic acid
CN115068418B (zh) *	2022-07-20	2022-10-28	奥信阳光(北京)药业科技有限公司	一种熊去氧胆酸口服溶液及其制备方法
WO2024144482A1 (en) *	2022-12-30	2024-07-04	Humanis Saglik Anonim Sirketi	Pharmaceutical oral suspension compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3639597A (en) *	1968-02-02	1972-02-01	Merck & Co Inc	Pharmaceutical compositions containing cholanic acid conjugates
DE2757641C2 (de) *	1977-12-23	1980-03-06	Rowa Ltd., Bantry, Cork (Irland)	Verwendung von cis-(33Ä-Trimethylcyclohexanol zur Behandlung von Galleleiden
JPS5522616A (en) *	1978-08-04	1980-02-18	Tokyo Tanabe Co Ltd	Bile acid inclusion compound and injection containing the same
US4264583A (en) *	1979-07-25	1981-04-28	The Procter & Gamble Company	Gallstone dissolution compositions and method
JPS62153220A (ja) *	1985-12-27	1987-07-08	Tokyo Tanabe Co Ltd	胆汁酸内用水剤
IT1245889B (it) *	1991-04-12	1994-10-25	Alfa Wassermann Spa	Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.

1994
- 1994-08-16 DK DK94810472T patent/DK0640344T3/da active
- 1994-08-16 EP EP94810472A patent/EP0640344B1/de not_active Expired - Lifetime
- 1994-08-16 AT AT94810472T patent/ATE171874T1/de active
- 1994-08-16 DE DE59407041T patent/DE59407041D1/de not_active Expired - Lifetime
- 1994-08-16 ES ES94810472T patent/ES2121599T3/es not_active Expired - Lifetime
- 1994-08-24 CA CA002130787A patent/CA2130787C/en not_active Expired - Fee Related
- 1994-08-25 US US08/296,355 patent/US5534505A/en not_active Expired - Lifetime
- 1994-08-26 JP JP20232994A patent/JP3631782B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2130787A1 (en)	1995-03-01
JPH0782150A (ja)	1995-03-28
EP0640344B1 (de)	1998-10-07
EP0640344A1 (de)	1995-03-01
US5534505A (en)	1996-07-09
ES2121599T3 (es)	1998-12-01
DE59407041D1 (de)	1998-11-12
JP3631782B2 (ja)	2005-03-23
ATE171874T1 (de)	1998-10-15
CA2130787C (en)	2006-12-05

Publication	Publication Date	Title
DK0640344T3 (da)	1999-07-05	Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform
DE3446873C2 (da)	1989-04-27
WO2002064148A3 (en)	2002-11-21	Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
KR940018089A (ko)	1994-08-16	내부조직의 방사선 손상에 대한 예방 및 처치방법
US4789660A (en)	1988-12-06	Insulin administration using methyl and propyl paraben
DE69913116T2 (de)	2004-06-03	Orale flüssige lösung enthaltend das antidepressivum mirtazapine
CY2503B1 (en)	2005-09-02	Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
KR20010034240A (ko)	2001-04-25	약학 조성물
RU2002135599A (ru)	2004-05-10	Способ повышения антиокислительного потенциала селенсодержащих водных растворов
ES2436213T3 (es)	2013-12-27	Una formulación en suspensión estable de clozapina
US5955456A (en)	1999-09-21	Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol
ATE178208T1 (de)	1999-04-15	Capsaicin enthaltendes arzneimittel zur behandlung chronischer rhinopathie
ATE241959T1 (de)	2003-06-15	Formulierungen von steroidlösungen zur inhalativen verabreichung
EP0050981A3 (en)	1982-06-23	Steroid-containing compositions and their topical uses
JPS60123426A (ja)	1985-07-02	経鼻投与用セクレチン製剤
JPH11139970A (ja)	1999-05-25	経口液剤
DE3502099A1 (de)	1986-08-07	Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel
RU96101227A (ru)	1998-03-27	Способ защиты растений сахарной свеклы от болезней
JPS62175427A (ja)	1987-08-01	塗布勃起剤
DK200000687A (da)	2000-10-28	Middel til forsøgelse af afgivelsen af cerebral acetylcholin
JPS63145226A (ja)	1988-06-17	メフエナム酸外用液剤
Bevan et al.	1978	Influence of impaired renal function on the disposition of [14C] fazadinium in the anaesthetized greyhound [proceedings]
RU92015142A (ru)	1995-03-10	Состав противомикробных суспензий
DE1620216A1 (de)	1970-04-02	Verfahren zur Herstellung eines Salzes des N-[gamma-(4'-methylpiperazinyl-1')-propyl]-3-butyrylphenothiazins
Lee et al.	1974	THE KININ-GENERATING SYSTEM IN LIPOID NEPHROSIS